Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F23%3A10158097" target="_blank" >RIV/00098892:_____/23:10158097 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/23:00131333 RIV/61989592:15110/23:73620447 RIV/65269705:_____/23:00079138

Výsledek na webu

<a href="https://haematologica.org/article/view/haematol.2022.282263" target="_blank" >https://haematologica.org/article/view/haematol.2022.282263</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2022.282263" target="_blank" >10.3324/haematol.2022.282263</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience

Popis výsledku v původním jazyce

For more than four decades, conventional therapy for acute myeloid leukemia (AML) has been cytarabine/anthracycline-containing regimens, followed by consolidation therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). In recent years, the approach to the treatment of AML has shifted significantly toward the use of novel and effective, target-directed therapies, including the anti-CD33 immunoconjugate, gemtuzumab ozogamicin (GO), and an inhibitor of mutant FMS-like tyrosine kinase 3 (FLT3), midostaurin. Our study&apos;s major strength is its unique focus on a homogeneous cohort of patients with FLT3-mutated/CD33+ AML treated with GO + midostaurin + IC at two academic hematology centers. The study limitations concern only the small number of evaluated cases. In summary, our data highlighted a high response rate and good tolerability with no evidence of increased toxicity (with the exception of slightly prolonged recovery of neutrophil count) of GO plus midostaurin added to standard IC in patients with newly diagnosed FLT3-mutated/CD33+ AML. Our results should be validated in a larger group of patients with a longer follow-up.

Název v anglickém jazyce

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience

Popis výsledku anglicky

For more than four decades, conventional therapy for acute myeloid leukemia (AML) has been cytarabine/anthracycline-containing regimens, followed by consolidation therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). In recent years, the approach to the treatment of AML has shifted significantly toward the use of novel and effective, target-directed therapies, including the anti-CD33 immunoconjugate, gemtuzumab ozogamicin (GO), and an inhibitor of mutant FMS-like tyrosine kinase 3 (FLT3), midostaurin. Our study&apos;s major strength is its unique focus on a homogeneous cohort of patients with FLT3-mutated/CD33+ AML treated with GO + midostaurin + IC at two academic hematology centers. The study limitations concern only the small number of evaluated cases. In summary, our data highlighted a high response rate and good tolerability with no evidence of increased toxicity (with the exception of slightly prolonged recovery of neutrophil count) of GO plus midostaurin added to standard IC in patients with newly diagnosed FLT3-mutated/CD33+ AML. Our results should be validated in a larger group of patients with a longer follow-up.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/LX22NPO5102" target="_blank" >LX22NPO5102: Národní ústav pro výzkum rakoviny</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

0390-6078

e-ISSN

1592-8721

Svazek periodika

108

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

4

Strana od-do

2826-2829

Kód UT WoS článku

001109389400037

EID výsledku v databázi Scopus

2-s2.0-85169139982